ATE19792T1 - Verfahren zur herstellung eines kolonspezifischen antigen p tryptischen peptides und von anti-kolon-spezifischen antigen p antikoerpern. - Google Patents

Verfahren zur herstellung eines kolonspezifischen antigen p tryptischen peptides und von anti-kolon-spezifischen antigen p antikoerpern.

Info

Publication number
ATE19792T1
ATE19792T1 AT82104604T AT82104604T ATE19792T1 AT E19792 T1 ATE19792 T1 AT E19792T1 AT 82104604 T AT82104604 T AT 82104604T AT 82104604 T AT82104604 T AT 82104604T AT E19792 T1 ATE19792 T1 AT E19792T1
Authority
AT
Austria
Prior art keywords
colon
specific antigen
antibodies
tryptic peptide
production
Prior art date
Application number
AT82104604T
Other languages
English (en)
Inventor
Milton David Goldenberg
Dan Shochat
Original Assignee
Milton David Goldenberg
Dan Shochat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Milton David Goldenberg, Dan Shochat filed Critical Milton David Goldenberg
Application granted granted Critical
Publication of ATE19792T1 publication Critical patent/ATE19792T1/de

Links

Classifications

    • G01N33/5753—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT82104604T 1981-06-01 1982-05-27 Verfahren zur herstellung eines kolonspezifischen antigen p tryptischen peptides und von anti-kolon-spezifischen antigen p antikoerpern. ATE19792T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/269,115 US4468457A (en) 1981-06-01 1981-06-01 Method for producing a CSAp tryptic peptide and anti-CSAp antibodies
EP82104604A EP0066786B1 (de) 1981-06-01 1982-05-27 Verfahren zur Herstellung eines Kolon-spezifischen Antigen P tryptischen Peptides und von anti-Kolon-spezifischen Antigen P Antikörpern

Publications (1)

Publication Number Publication Date
ATE19792T1 true ATE19792T1 (de) 1986-05-15

Family

ID=23025864

Family Applications (1)

Application Number Title Priority Date Filing Date
AT82104604T ATE19792T1 (de) 1981-06-01 1982-05-27 Verfahren zur herstellung eines kolonspezifischen antigen p tryptischen peptides und von anti-kolon-spezifischen antigen p antikoerpern.

Country Status (9)

Country Link
US (1) US4468457A (de)
EP (1) EP0066786B1 (de)
JP (1) JPS58501355A (de)
AT (1) ATE19792T1 (de)
AU (1) AU550306B2 (de)
CA (1) CA1183451A (de)
DE (1) DE3271119D1 (de)
IL (1) IL65915A (de)
WO (1) WO1982004263A1 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4454106A (en) * 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
US4472509A (en) * 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
DE3432714A1 (de) * 1984-09-06 1986-04-24 Behringwerke Ag, 3550 Marburg Tumortherapeutikum und verfahren zu seiner herstellung
US4962187A (en) * 1984-11-28 1990-10-09 Cota Biotech Common antigen for colorectal and mucinous ovarian tumors and process for isolating the same
NO861491L (no) * 1985-04-22 1986-10-23 Hybritech Inc Antistoff, fremgangsmaate for dets fremstilling og anvendelse for deteksjon og diagnose av canser.
ES8800604A1 (es) * 1985-04-22 1987-11-16 Hybritech Inc Un metodo para producir anticuerpos monoclonales
US5776093A (en) * 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
DK169987D0 (da) * 1987-04-03 1987-04-03 Jens Christian Jensenius Human tumor-associated antigen, ca-ou1
CA1329119C (en) * 1988-03-29 1994-05-03 Milton David Goldenberg Cytotoxic therapy
ES2245778T3 (es) * 1993-08-11 2006-01-16 Jenner Technologies Vacuna contra el cancer de prostata.
US7011812B1 (en) * 1996-05-03 2006-03-14 Immunomedics, Inc. Targeted combination immunotherapy of cancer and infectious diseases
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
WO1999059633A1 (en) 1998-05-20 1999-11-25 Immunomedics, Inc. Therapeutics using a bispecific anti-hla class ii invariant chain x anti-pathogen antibody
US6962702B2 (en) * 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
US7387772B1 (en) * 1999-06-22 2008-06-17 Immunimedics, Inc. Chimeric, human and humanized anti-CSAP monoclonal antibodies
US7405320B2 (en) 1998-06-22 2008-07-29 Immunomedics, Inc. Therapeutic and diagnostic conjugates for use with multispecific antibodies
US7833528B2 (en) * 1998-06-22 2010-11-16 Immunomedics, Inc. Use of multispecific, non-covalent complexes for targeted delivery of therapeutics
US7138103B2 (en) * 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US6361774B1 (en) 1999-09-17 2002-03-26 Immunomedics, Inc. Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
DK1247095T3 (da) 1999-12-06 2008-12-08 Univ Illinois TCR-proteiner med höj affinitet samt fremgangsmåder
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
WO2001097855A2 (en) * 2000-06-20 2001-12-27 Immunomedics, Inc. Targeted combination immunotherapy of cancer and infectious diseases
US20020165149A1 (en) * 2000-12-08 2002-11-07 Kranz David M. Mutated class II major histocompatibility proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
WO2002078638A2 (en) * 2001-03-30 2002-10-10 University Of Massachusetts Morpholino imaging and therapy
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
AU2003248747A1 (en) 2002-06-27 2004-01-19 Health Research, Inc. Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
AU2003249742A1 (en) 2002-07-02 2004-01-23 Health Research, Inc. Efficient synthesis of pyropheophorbide a and its derivatives
US20060024289A1 (en) * 2002-10-02 2006-02-02 Ruggles Sandra W Cleavage of VEGF and VEGF receptor by wild-type and mutant proteases
US7939304B2 (en) * 2002-10-02 2011-05-10 Catalyst Biosciences, Inc. Mutant MT-SP1 proteases with altered substrate specificity or activity
ATE517638T1 (de) 2003-01-31 2011-08-15 Immunomedics Inc Verfahren und zubereitungen zum verabreichen von therapeutischen und diagnostischen mitteln
US7057100B2 (en) * 2003-06-26 2006-06-06 The J.C. Robinson Seed Co. Inbred corn line W23129
JP2007524649A (ja) * 2003-07-29 2007-08-30 イミューノメディクス、インコーポレイテッド フッ素化炭水化物複合体
CN101501211A (zh) 2004-03-31 2009-08-05 综合医院公司 测定癌症对表皮生长因子受体靶向性治疗反应性的方法
DK1735439T3 (da) * 2004-04-12 2012-02-06 Catalyst Biosciences Inc Spaltning af VEGF og VEGF receptor ved hjælp af vild-type og mutant MT-SP1
US20050260131A1 (en) * 2004-05-20 2005-11-24 General Electric Company Pharmaceuticals for enhanced delivery to disease targets
RS53318B (sr) 2005-07-25 2014-10-31 Emergent Product Development Seattle, Llc Smanjenje broja b-ćelija upotrebom cd37-specifično i cd20-specifično vezujućih molekula
EP2674440B1 (de) 2005-12-16 2019-07-03 IBC Pharmaceuticals, Inc. Polyvalente bioaktive anordnungen auf immunglobulinbasis
NZ573646A (en) 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
ES2721266T3 (es) * 2006-07-05 2019-07-30 Catalyst Biosciences Inc Procedimientos de cribado de proteasas y proteasas identificadas por los mismos
JP6013733B2 (ja) 2008-04-11 2016-10-25 エマージェント プロダクト デベロップメント シアトル， エルエルシー Ｃｄ３７免疫治療薬および二機能性化学療法薬とのその組合せ
ES2738700T3 (es) 2009-02-13 2020-01-24 Immunomedics Inc Inmunoconjugados con un enlace escindible intracelularmente
US8012770B2 (en) 2009-07-31 2011-09-06 Invisible Sentinel, Inc. Device for detection of antigens and uses thereof
WO2011044186A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
WO2011044574A1 (en) 2009-10-09 2011-04-14 Invisible Sentinel Device for detection of antigens and uses thereof
CA2826095C (en) 2011-01-27 2020-06-23 Invisible Sentinel, Inc. Analyte detection devices, multiplex and tabletop devices for detection of analytes, and uses thereof
WO2013096455A1 (en) 2011-12-20 2013-06-27 Dana-Farber Cancer Institute, Inc. Methods for diagnosing and treating oncogenic kras-associated cancer
CA2866379C (en) 2012-03-09 2020-10-13 Invisible Sentinel, Inc. Methods and compositions for detecting multiple analytes with a single signal
CA2874521A1 (en) 2012-05-24 2013-11-28 Dana-Farber Cancer Institute, Inc. Targeting the glutamine to pyruvate pathway for treatment of oncogenic kras-associated cancer
US20150285802A1 (en) 2012-07-18 2015-10-08 Dana-Farber Cancer Institute, Inc. Methods for treating, preventing and predicting risk of developing breast cancer
KR102250696B1 (ko) 2012-07-27 2021-05-12 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 Ｔ 세포 수용체 조작
US9315567B2 (en) 2012-08-14 2016-04-19 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
CA3177936A1 (en) 2012-12-13 2014-06-19 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
WO2014124307A2 (en) 2013-02-08 2014-08-14 The Regents Of The University Of Michigan Targeted theranostics
CN105722850B (zh) 2013-08-19 2020-03-06 雅培分子公司 核苷酸类似物
US10130590B2 (en) 2013-10-01 2018-11-20 Dana-Farber Cancer Institute, Inc. Methods of treating cancer with atovaquone-related compounds
SG10201804335QA (en) 2013-11-22 2018-06-28 Univ Illinois Engineered high-affinity human t cell receptors
WO2015149006A2 (en) 2014-03-27 2015-10-01 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating ncoa4-mediated autophagic targeting of ferritin
PL3258931T3 (pl) 2015-02-17 2020-12-28 Erasmus University Medical Center Rotterdam Zastosowanie kabazitakselu w leczeniu nowotworu złośliwego prostaty
PL3316885T3 (pl) 2015-07-01 2021-12-06 Immunomedics, Inc. Immunokoniugaty przeciwciało-sn-38 z linkerem cl2a
UA126278C2 (uk) 2015-09-21 2022-09-14 Аптево Рісьорч Енд Девелопмент Ллс Поліпептиди, які зв'язують cd3
WO2017151836A1 (en) 2016-03-04 2017-09-08 East Carolina University J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
US10919904B2 (en) 2016-08-17 2021-02-16 North Carolina State University Northern-southern route to synthesis of bacteriochlorins
WO2018102252A1 (en) 2016-11-30 2018-06-07 North Carolina State University Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
US11571401B2 (en) 2017-09-01 2023-02-07 East Carolina University Compounds, compositions, kits, and methods for activating immune cells and/or an immune system response
CA3138403A1 (en) 2019-05-20 2020-11-26 Christopher J. MACNEVIN Narrow emission dyes, compositions comprising same, and methods for making and using same
ES3036313T3 (en) 2019-05-20 2025-09-17 Nirvana Sciences Inc Narrow emission dyes, compositions comprising same, and methods for making and using same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2719102A (en) * 1949-10-28 1955-09-27 Corn States Serum Company Clostridium perfringens toxoid and process of making the same
US4086217A (en) * 1976-03-03 1978-04-25 Hoffmann-La Roche Inc. Carcinoembryonic antigens
US4228236A (en) * 1978-05-15 1980-10-14 Northwestern University Process of producing carcinoembryonic antigen

Also Published As

Publication number Publication date
US4468457A (en) 1984-08-28
IL65915A (en) 1985-07-31
IL65915A0 (en) 1982-08-31
CA1183451A (en) 1985-03-05
DE3271119D1 (en) 1986-06-19
WO1982004263A1 (en) 1982-12-09
EP0066786B1 (de) 1986-05-14
EP0066786A2 (de) 1982-12-15
AU8731882A (en) 1982-12-07
JPS58501355A (ja) 1983-08-18
EP0066786A3 (en) 1983-07-20
AU550306B2 (en) 1986-03-13

Similar Documents

Publication Publication Date Title
ATE19792T1 (de) Verfahren zur herstellung eines kolonspezifischen antigen p tryptischen peptides und von anti-kolon-spezifischen antigen p antikoerpern.
KR900009095A (ko) 합성 항원, 이의 제조방법 및 용도
ES8305419A1 (es) Un peptido
ES2006941A6 (es) Un metodo de producir un peptido o una proteina relacionados con un epitope de virus asociado a linfoadenopatiasnvirus de leucemia de celulas t humanas (lavnhtlv-iii).
DE69110663D1 (de) Verfahren zur herstellung eines enzymhydrolysates.
DE69434811D1 (de) Monoklonale antikörper gegen phf-tau, hybridomen die diese ausscheiden, antigenerkennung durch diesen antikörper und deren verwendungen
DK0461177T3 (da) Humant intra-acrosomalt spermantigen til anvendelse i en svangerskabsforebyggende vaccine
SE8205313L (sv) Antigen-proteinkomplex for blockering av allergiska reaktioner samt sett for framstellning derav
DE59107901D1 (de) Verfahren zur herstellung gereinigter glycolipide durch membrantrennverfahren
DE3788229D1 (de) Verfahren zur isolierung von ca 125-antigen.
DE69101281D1 (de) Tieftemperatur-Lufttrennung zur Erzeugung von druckerhöhtem Produktgas.
KR840009069A (ko) 향정신성 펩티드류의 제조 방법
SE8103198L (sv) Forfarande for framstellning av antikroppar
ATE5592T1 (de) Verfahren zur herstellung von 4'deoxydaunorubicin und 4'-deoxydoxorubicin, sowie 4'-epi-4'-trifluormethyl-sulfonyloxy-ntrifluoracetyldaunorubicin.
GB1375811A (de)
DE69738770D1 (de) Porphyromonas gingivalis Antigene zur Diagnose und Behandlung von Periodontitis
JPS5657753A (en) Novel glucagon fragment, and its use
AU612683B2 (en) Synthetic peptides, antibodies directed against them, and the use thereof
NO900758D0 (no) Fremgangsmaate for fremstilling av hybridprotein.
ES443969A1 (es) Procedimiento de preparacion de un agente peptidico de regu-lacion de la glucemia.
KR840002346A (ko) 펩타이드의 제조방법
SU646162A1 (ru) Способ разделени природного и попутного газов
SU587977A1 (ru) Способ очистки газа от сероводорода
PT73587A (en) Process for preparing novel peptides
PT79232A (en) Process for producing immune interferon and of pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties